Scotiabank lowers Sabra Health Care REIT target to $19
Scotiabank analyst Nicholas Yulico maintained Sabra Health Care REIT with a Sector Perform rating and lowered the price target to $19 from $22.

*this image is generated using AI for illustrative purposes only.
Scotiabank analyst Nicholas Yulico maintained Sabra Health Care REIT with a Sector Perform rating while lowering the price target to $19 from $22. The adjustment reflects a revised outlook for the healthcare real estate investment trust.
The rating remains unchanged as Sector Perform, indicating an expectation for the stock to perform in line with the broader sector. The price target reduction suggests a more conservative valuation of the company's near-term potential.
| Metric | Previous | New |
|---|---|---|
| Price Target | $22 | $19 |
| Rating | Sector Perform | Sector Perform |
What specific factors led to the revised outlook for Sabra Health Care REIT's near-term potential?
How might this price target reduction influence investor sentiment towards the healthcare REIT sector?
What are the potential risks or challenges facing Sabra Health Care REIT in the current market environment?

























